首页> 外文OA文献 >Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin’s Lymphoma

【2h】

Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin’s Lymphoma

机译：EBI-2511的发现：一种高效且口服活性的EZH2抑制剂，用于治疗非霍奇金淋巴瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Biao Lu; Xiaodong Shen; Lei Zhang; Dong Liu; Caihua Zhang; Jingsong Cao; Ru Shen; Jiayin Zhang; Dan Wang; Hong Wan; Zhibin Xu; Ming-Hsun Ho; Minsheng Zhang; Lianshan Zhang; Feng He; Weikang Tao;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma [J] . Lu Biao, Shen Xiaodong, Zhang Lei, ACS medicinal chemistry letters . 2018,第2期

机译：EBI-2511的发现：一种高效和口服活性的EZH2抑制剂，用于治疗非霍奇金淋巴瘤
2. Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, Reversible, and Orally Active Monoamine Oxidase B Inhibitor [J] . Pisani L, Muncipinto G, Miscioscia TF, Journal of Medicinal Chemistry . 2009,第21期

机译：一类新型强力香豆素单胺氧化酶B抑制剂的发现：7-[（3-氯苄基）氧基] -4-[（甲基氨基）甲基] -2H-铬-2-酮甲烷磺酸盐（NW-1772）的开发和生物药理学分析）作为高效，选择性，可逆和口服活性单胺氧化酶B抑制剂
3. Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers [J] . Lu Biao, Cao Hu, Cao Jingsong, Bioorganic and Medicinal Chemistry Letters . 2016,第3期

机译：EBI-907的发现：一种高效和口服活性的B-RAF（V600E）抑制剂，用于治疗黑素瘤和相关癌症
4. Development of Single Domain Antibodies for Diagnosis and Treatment of Naturally Occurring Canine Lymphoma: An Animal Model for Human Non-Hodgkin Lymphoma [C] . Joana Dias, Solange Gil, Belmira Carrapico, PEGS . 2015

机译：天然犬淋巴瘤诊断和治疗单结构域抗体的发展：人非霍奇金淋巴瘤的动物模型
5. Targeting the translational machinery as a novel treatment strategy for non-Hodgkin lymphoma. [D] . Hagner, Patrick R. 2010

机译：针对非霍奇金淋巴瘤的新型治疗策略，以翻译机制为目标。
6. Discovery of EBI-2511: A Highly Potent and OrallyActive EZH2 Inhibitor for the Treatment of Non-Hodgkin’s Lymphoma [O] . Biao Lu, *, Xiaodong Shen, 2018

机译：EBI-2511的发现：高效口服活性EZH2抑制剂治疗非霍奇金淋巴瘤
7. Discovery of a Highly Potent, Orally Active Mitosis/Angiogenesis Inhibitor R1530 for the Treatment of Solid Tumors [O] . Jin-Jun Liu, Brian Higgins, Grace Ju, 2013

机译：发现高效，口服有丝分裂/血管生成抑制剂R1530，用于治疗实体肿瘤

Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin’s Lymphoma

著录项

引文网络

相似文献

相关主题

期刊订阅